Proprietary Data Used to Highlight Likelihood of Drug Approval and Competitive Landscape

Companies Profiled Include: CEPH GENZ PFE BMY BIIB MRK SHPGY CELG ELN NBIX

New York, April 17, 2006 – Revere Data, LLC, a fast-growing provider of independent research data and investment analytics, today announced an updated Revere Data Report that identifies companies with expected FDA drug approval decision dates (commonly known as PDUFA dates) from April 2006 through June 2006. Data from Revere Data’s patented classification system and proprietary drug pipeline database is included to provide insights into each drug candidate’s likelihood of approval and the competition it will face.

The FDA Approval Decisions Report is designed to generate ideas for trading and investment opportunities in the Biopharmaceuticals sector. The Report is available for purchase on Revere Data’s website at www.reveredata.com/reports/store/report/fda/FDA200604. For current Revere subscribers, the FDA Approvals report is available in the new Reports section of Revere Research™.

“For investors monitoring the drug development pipelines of pharmaceutical and biotech companies, no milestone is more influential than the PDUFA date,” noted Brian Hill , Director of Research for Revere Data. “Using this calendar and Revere Data’s exclusive content, customers can quickly focus on companies that have potentially high-impact events in the April to June timeframe.”

Specifically, the FDA Approval Decisions Report provides a three-month calendar (covering April to June 2006) of expected PDUFA dates, along with detail on whether each drug candidate:

1. utilizes a mechanism of action already approved by the FDA in other drugs
2. faces two or fewer alternative drugs with the same mechanism of action for the same indication
3. would be the first or second FDA-approved drug for the company

“When drugs meet the above criteria, we have seen evidence that they are more likely to gain approval, and to positively impact the company’s stock price,” explained Hill. “Attempting to track and assess these drugs without Revere Data would be hugely time-consuming.”

Revere Data offers clients the flexibility to access its exclusive content through Revere Research, a user-friendly web based platform or Revere Datafeed, data files that can be integrated into research and trading applications as well as algorithms. With either application, users gain access to Revere Data’s intelligent database of U.S publicly traded companies and ADR’s not available through other research providers. Revere Data’s clientele includes sellside agency and proprietary traders, buyside
traders, hedge fund managers, portfolio managers, equity analysts, and other professionals at leading financial institutions, along with competitive intelligence, business development, and strategy specialists at major corporations.


Revere Data, LLC, provides finance and business professionals with superior data and analytics for companies traded publicly on U.S. exchanges. The Revere Data approach is based on precise product and industry classification and identification of key business relationships. Revere Data’s datafeeds and its research and real-time trading applications feature unique content derived from Revere Data’s own independent research: the Revere Hierarchy™, a patented classification system that provides unmatched detail in specifying a company’s business activities and identifying exact competitors, and Revere Relationships™, a database mapping a company to its key competitors, customers, suppliers, and strategic partners. For more information, please visit www.reveredata.com.